Warfarin in the Secondary Prevention of Thromboembolism in Atrial Fibrillation: Impact of Bioavailability on Costs and Outcomes

Author： Nicole Mittmann   Paul I. Oh   Scott E. Walker   William R. Bartle  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.22, Iss.10, 2004-01, pp. : 671-683

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves

By Marcy Todd R.   Truong Teresa   Rai Andrea  

The Consultant Pharmacist, Vol. 30, Iss. 11, 2015-11 ,pp. : 644-656

American Society of Consultant Pharmacists

Access to resources Recommend Favorite

Barriers to warfarin use in atrial fibrillation

By  

Inpharma, Vol. 1, Iss. 1224, 2000-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Secondary Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Optimal Intensity of Anticoagulation

By Yasaka M.   Yamaguchi T.  

CNS Drugs, Vol. 15, Iss. 8, 2001-01 ,pp. : 623-631

Adis International

Access to resources Recommend Favorite

Current Therapeutic Strategies and Future Perspectives for the Prevention of Arterial Thromboembolism: Focus on Atrial Fibrillation

By  

Current Pharmaceutical Design, Vol. 16, Iss. 31, 2010-10 ,pp. : 3455-3471

Bentham Science Publishers

Access to resources Recommend Favorite

Effect of Race/Ethnicity on the Efficacy of Warfarin: Potential Implications for Prevention of Stroke in Patients with Atrial Fibrillation

By Shen Albert Yuh-Jer  

CNS Drugs, Vol. 22, Iss. 10, 2008-01 ,pp. : 815-825

Adis International

Access to resources Recommend Favorite